目的:探讨钩藤方治疗阳亢热毒证原发性高血压伴焦虑障碍的临床疗效及对炎症平衡的影响。方法:将98例诊断为原发性高血压伴焦虑症患者,随机分为两组,在高血压常规西医治疗基础上,对照组(47例)给予疏肝解郁胶囊治疗8周,观察组(51例)予以...目的:探讨钩藤方治疗阳亢热毒证原发性高血压伴焦虑障碍的临床疗效及对炎症平衡的影响。方法:将98例诊断为原发性高血压伴焦虑症患者,随机分为两组,在高血压常规西医治疗基础上,对照组(47例)给予疏肝解郁胶囊治疗8周,观察组(51例)予以中药钩藤方治疗8周。比较两组患者血压水平、24 h血压变异性、汉密尔顿焦虑量表(HAMA)、匹兹堡睡眠质量指数(PSQI)、生活质量(SF-36量表)、中医证候积分及疗效、不良反应发生率,并检测外周血清白细胞介素(IL)-1β、IL-6、IL-10、IL-4水平。结果:最终完成试验观察病例95例,对照组46例,观察组49例。与本组治疗前比较,两组血压、血压变异性均降低(P<0.05,P<0.01);治疗后与对照组比较,观察组收缩压(SBP)、24 h平均收缩压(24 h SBP)、24 h收缩压变异性(24 h SBPV)、24 h舒张压变异性(24 h DBPV)改善程度优于对照组(P<0.05)。与本组治疗前比较,两组治疗后HAMA、PSQI评分均下降(P<0.05,P<0.01);治疗后与对照组比较,观察组HAMA、PSQI指标下降更明显(P<0.05)。与本组治疗前比较,两组治疗后SF-36生活质量评分均提高(P<0.05,P<0.01);治疗后与对照组比较,观察组生理功能(PF)、躯体疼痛(BP)、社会功能(SF)、情感职能(RE)、精神健康(MH)指标显著升高(P<0.05)。与本组治疗前比较,两组治疗后中医证候积分均下降(P<0.05,P<0.01)。治疗后与对照组比较,观察组中医证候积分明显降低(P<0.05)。观察组中医证候总有效率85.71%(42/49),对照组总有效率63.04%(29/46),观察组总有效率优于对照组(χ^(2)=6.621,P<0.05)。与本组治疗前比较,两组治疗后促炎因子(IL-1β、IL-6)水平下降,抑炎因子(IL-10、IL-4)水平升高(P<0.05,P<0.01);治疗后与对照组比较,观察组IL-1β、IL-6、IL-10、IL-4改善程度优于对照组(P<0.05)。研究过程无不良事件发生。结论:钩藤方能改善阳亢热毒证原发性高血压伴焦虑障碍患者的血压水平,降低血压变异性,抑制焦虑状态,提高睡眠及生活质量,改善中医证候积分及总有效率,降低血清IL-1β、IL-6水平,升高血清IL-10、IL-4水平,其作用机制可能与调节促炎/抗炎平衡有关。展开更多
In this work, the preparation of chitosan-poly(acrylic acid)-calcium phosphate hybrid nanoparticles (CS-PAA-CaP NP) based on the mineralization of calcium phosphate (CaP) on the surface of chito-san-poly (acrylic acid...In this work, the preparation of chitosan-poly(acrylic acid)-calcium phosphate hybrid nanoparticles (CS-PAA-CaP NP) based on the mineralization of calcium phosphate (CaP) on the surface of chito-san-poly (acrylic acid) nanoparticles (CS-PAA NPs) was reported. CS-PAA-CaP NPs were achieved by directly adding ammonia to the aqueous solution of CS-PAA nanoparticles or by thermal decomposi-tion of urea in the aqueous solution of CS-PAA nanoparticles, resulting in the mineralization of CaP on the surface of CS-PAA NPs. Through these two routes, especially using urea as a pH-regulator, the precipitation of CS-PAA NPs, a common occurrence in basic environment, was avoided. The size, morphology and ingredient of CS-PAA-CaP hybrid nanoparticles were characterized by dynamic light scattering (DLS), transmission electron microscope (TEM), scanning electron microscope (SEM), thermogravimetry analysis (TGA) and X-ray diffractometer (XRD). When urea was used as the pH regulator to facilitate the mineralization during the thermal urea decomposition procedure, regular CS-PAA-CaP hybrid nanoparticles with a porosity-structural CaP shells and 400―600 nm size were obtained. TGA result revealed that the hybrid NPs contained approximately 23% inorganic component, which was consistent with the ratio of starting materials. The XRD spectra of hybrid nanoparticles in-dicated that dicalcium phosphate (DCP: CaHPO4) crystal was a dominant component of mineralization. The porous structure of the CS-PAA-CaP hybrid NPs might be greatly useful in pharmaceutical and other medical applications.展开更多
文摘目的:探讨钩藤方治疗阳亢热毒证原发性高血压伴焦虑障碍的临床疗效及对炎症平衡的影响。方法:将98例诊断为原发性高血压伴焦虑症患者,随机分为两组,在高血压常规西医治疗基础上,对照组(47例)给予疏肝解郁胶囊治疗8周,观察组(51例)予以中药钩藤方治疗8周。比较两组患者血压水平、24 h血压变异性、汉密尔顿焦虑量表(HAMA)、匹兹堡睡眠质量指数(PSQI)、生活质量(SF-36量表)、中医证候积分及疗效、不良反应发生率,并检测外周血清白细胞介素(IL)-1β、IL-6、IL-10、IL-4水平。结果:最终完成试验观察病例95例,对照组46例,观察组49例。与本组治疗前比较,两组血压、血压变异性均降低(P<0.05,P<0.01);治疗后与对照组比较,观察组收缩压(SBP)、24 h平均收缩压(24 h SBP)、24 h收缩压变异性(24 h SBPV)、24 h舒张压变异性(24 h DBPV)改善程度优于对照组(P<0.05)。与本组治疗前比较,两组治疗后HAMA、PSQI评分均下降(P<0.05,P<0.01);治疗后与对照组比较,观察组HAMA、PSQI指标下降更明显(P<0.05)。与本组治疗前比较,两组治疗后SF-36生活质量评分均提高(P<0.05,P<0.01);治疗后与对照组比较,观察组生理功能(PF)、躯体疼痛(BP)、社会功能(SF)、情感职能(RE)、精神健康(MH)指标显著升高(P<0.05)。与本组治疗前比较,两组治疗后中医证候积分均下降(P<0.05,P<0.01)。治疗后与对照组比较,观察组中医证候积分明显降低(P<0.05)。观察组中医证候总有效率85.71%(42/49),对照组总有效率63.04%(29/46),观察组总有效率优于对照组(χ^(2)=6.621,P<0.05)。与本组治疗前比较,两组治疗后促炎因子(IL-1β、IL-6)水平下降,抑炎因子(IL-10、IL-4)水平升高(P<0.05,P<0.01);治疗后与对照组比较,观察组IL-1β、IL-6、IL-10、IL-4改善程度优于对照组(P<0.05)。研究过程无不良事件发生。结论:钩藤方能改善阳亢热毒证原发性高血压伴焦虑障碍患者的血压水平,降低血压变异性,抑制焦虑状态,提高睡眠及生活质量,改善中医证候积分及总有效率,降低血清IL-1β、IL-6水平,升高血清IL-10、IL-4水平,其作用机制可能与调节促炎/抗炎平衡有关。
基金Supported by the National Natural Science Foundation of China (Grant Nos. 50603008, 50625311)National High-Tech Research & Development Program of China (Grant No. 2007AA100704)Cultivation Fund of Key Scientific and Technical Innovation Project,Ministry of Education of China (Grant No. 707028)
文摘In this work, the preparation of chitosan-poly(acrylic acid)-calcium phosphate hybrid nanoparticles (CS-PAA-CaP NP) based on the mineralization of calcium phosphate (CaP) on the surface of chito-san-poly (acrylic acid) nanoparticles (CS-PAA NPs) was reported. CS-PAA-CaP NPs were achieved by directly adding ammonia to the aqueous solution of CS-PAA nanoparticles or by thermal decomposi-tion of urea in the aqueous solution of CS-PAA nanoparticles, resulting in the mineralization of CaP on the surface of CS-PAA NPs. Through these two routes, especially using urea as a pH-regulator, the precipitation of CS-PAA NPs, a common occurrence in basic environment, was avoided. The size, morphology and ingredient of CS-PAA-CaP hybrid nanoparticles were characterized by dynamic light scattering (DLS), transmission electron microscope (TEM), scanning electron microscope (SEM), thermogravimetry analysis (TGA) and X-ray diffractometer (XRD). When urea was used as the pH regulator to facilitate the mineralization during the thermal urea decomposition procedure, regular CS-PAA-CaP hybrid nanoparticles with a porosity-structural CaP shells and 400―600 nm size were obtained. TGA result revealed that the hybrid NPs contained approximately 23% inorganic component, which was consistent with the ratio of starting materials. The XRD spectra of hybrid nanoparticles in-dicated that dicalcium phosphate (DCP: CaHPO4) crystal was a dominant component of mineralization. The porous structure of the CS-PAA-CaP hybrid NPs might be greatly useful in pharmaceutical and other medical applications.